Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Abstract Type 1 diabetes (T1D) is an autoimmune disease characterized by immune-mediated destruction of insulin- producing pancreatic beta cells. Although the gut microbiota are recognized as critical environmental modulators of immune tolerance, the specific microbial contributors to T1D remain poorly defined. Our recent metagenomic analyses revealed that children with newly diagnosed T1D harbor significantly higher levels of gut microbial antibiotic resistance genes (ARGs), particularly those conferring resistance to erythromycin. Consistent with this observation, erythromycin-treated non-obese diabetic (NOD) mice displayed accelerated diabetes onset. 16S rRNA sequencing further identified a marked expansion of Parasutterella, a poorly characterized, low-abundance genus. We successfully isolated a novel erythromycin-resistant Parasutterella strain from feces of erythromycin-treated NOD mice. Average nucleotide identity (ANI) analysis indicates that this isolate represents a new species. Strikingly, mono-colonization of germ-free NOD mice with this isolate significantly accelerate diabetes development. In contrast, another erythromycin-resistant new isolate, Escherichia-Shigella, did affect T1D development, highlighting the strain-specific diabetogenic potential of Parasutterella. Moreover, fluorescent in situ hybridization (FISH) detected bacterial 16s rDNA within pancreatic tissue from Parasutterella mono- colonized germ-free NOD mice, suggesting bacterial translocation that may directly or indirectly contribute to b- cell damage. The proposed research will investigate the diabetogenic potential of the novel Parasutterella isolate and elucidated the underlying immunopathogenic mechanisms through two specific aims. Aim 1 will define the isolate’s mechanism of action on islet b-cells in vitro and in vivo with a focus on identifying Parasutterella-derived metabolites. Aim 2 will characterize the host immune response to the novel Parasutterella isolate in vivo and in situ, emphasizing molecular pathways using spatial multi-omics approaches (microDBiT-seq and spatial CITE- seq).
Grant Summary
Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $252K for university, nonprofit, healthcare org. Applications are due 2028-06-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $252K
2028-06-30
- 1Confirm your organization is eligible for Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes: Frequently Asked Questions
Who is eligible for the Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes?
Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes provide?
Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes provides up to $252K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes deadline?
Applications for Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes are due 2028-06-30 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes?
To apply for Discovery of a novel antibiotic-resistant gut microbe that accelerates type 1 diabetes, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.